EUCTR2008-000862-21-DE进行中（未招募）不适用
A 12 week, double-blind, randomized, parallel group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren 300 mg and hydrochlorothiazide 25 mg compared to aliskiren 300 mg in patients with Stage II hypertension
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 660
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patients must give written informed consent before any assessment is performed.
- •2. Outpatients =18 years of age.
- •3. Patients with a diagnosis of Stage II hypertension, defined as msSBP = 160 mmHg and < 180 mmHg at Visit 2.
- •4. Patients who are eligible, able to participate in the study, and who consent to do so after the purpose and nature of the investigation has been clearly explained to them
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •For full list, please refer to the protocol.
- •1. Severe hypertension defined as msSBP = 180 mmHg and/or msDBP = 110 mmHg.
- •2. History or evidence of secondary hypertension of any etiology (e.g., uncorrected renal artery stenosis, pheocromocitoma).
- •3. Current diagnosis of heart failure (NYHA Class II-IV).
- •4. Current angina pectoris requiring pharmacological therapy (other than stable doses of oral or topical nitrates).
- •5. Second or third degree heart block without a pacemaker.
- •6. Concurrent potentially life threatening arrhythmia or symptomatic arrhythmia, atrial
- •fibrillation or atrial flutter, during the 12 months prior to Visit 1.
- •7. Clinically significant valvular heart disease.
- •8. History of hypertensive encephalopathy or cerebrovascular accident, transient ischemic cerebral attack, coronary bypass surgery, myocardial infarction or any percutaneous coronary intervention (PCI).
- •9. Known Keith-Wagener grade III or IV hypertensive retinopathy.
- •10. In the month prior to Visit 1, patients on combination antihypertensive therapy that includes more than 2 classes of antihypertensive medications. Patients on combined antihypertensive medication that contain two classes of antihypertensive medications are considered to take two antihypertensive medications.
- •11. Administration of any agent indicated for the treatment of hypertension after Visit 1 with the exception of those agents that require tapering down.
- •12. History of angioedema due to ACE-Is or ARBs administration.
- •13. Patients with Type 1 diabetes mellitus.
- •14. Patients with Type 2 diabetes mellitus who are not well controlled based on
- •investigator’s clinical judgment. Patients currently being treated for diabetes mellitus
- •must have satisfactory metabolic control. Type 2 diabetic patients taking oral antidiabetic medication must be on a stable dose for at least 4 weeks prior to Visit 1.
- •15. Serum sodium less than the lower limit of normal, serum potassium < 3.5 mEq/L
- •(corresponding to 3.5 mmol/L) or = 5.3 mEq/L (corresponding to 5.3 mmol/L), or
- •dehydration at Visit 1.
研究者
相似试验
进行中（未招募）
不适用
A 12 week, double-blind, randomized, parallel group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren 300 mg and hydrochlorothiazide 25 mg compared to aliskiren 300 mg in patients with Stage II hypertension - NDhypertensionEUCTR2008-000862-21-ITOVARTIS FARMA660
进行中（未招募）
1 期
A 12-week, double-blind, randomised, parallel group, multi-centre, study to evaluate efficacy and safety of budesonide/formoterol (Symbicort® Turbuhaler®) 320/9 µg one inhalation twice daily on top of tiotropium (Spiriva®) 18 µg one inhalation once daily compared with tiotropium 18 µg one inhalation once daily, in patients with severe chronic obstructive pulmonary disease (COPD) - CLIMBSevere Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 9.1Level: LLTClassification code 10010952Term: COPDEUCTR2006-006796-21-SKAstraZeneca AB620
进行中（未招募）
不适用
A 12-week, double-blind, randomised, parallel group, multi-centre, study to evaluate efficacy and safety of budesonide/formoterol (Symbicort® Turbuhaler®) 320/9 µg one inhalation twice daily on top of tiotropium (Spiriva®) 18 µg one inhalation once daily compared with tiotropium 18 µg one inhalation once daily, in patients with severe chronic obstructive pulmonary disease (COPD) - CLIMBSevere Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 9.1Level: LLTClassification code 10010952Term: COPDEUCTR2006-006796-21-DEAstraZeneca AB620
进行中（未招募）
不适用
A 12-week, double-blind, randomised, parallel group, multi-centre, study to evaluate efficacy and safety of budesonide/formoterol (Symbicort® Turbuhaler®) 320/9 µg one inhalation twice daily on top of tiotropium (Spiriva®) 18 µg one inhalation once daily compared with tiotropium 18 µg one inhalation once daily, in patients with severe chronic obstructive pulmonary disease (COPD) - CLIMBSevere Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 9.1Level: LLTClassification code 10010952Term: COPDEUCTR2006-006796-21-HUAstraZeneca AB620
进行中（未招募）
1 期
A 12-week, double-blind, randomised, parallel group, multi-centre, study to evaluate efficacy and safety of budesonide/formoterol (Symbicort® Turbuhaler®) 320/9 µg one inhalation twice daily on top of tiotropium (Spiriva®) 18 µg one inhalation once daily compared with tiotropium 18 µg one inhalation once daily, in patients with severe chronic obstructive pulmonary disease (COPD) - CLIMBEUCTR2006-006796-21-FRAstraZeneca AB620